Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma

LaRocca, Christopher J.; Salzwedel, Amanda O.; Sato-Dahlman, Mizuho; Romanenko, Margarita V.; Andrade, Rafael S.; Davydova, Julia; Yamamoto, Masato

doi:10.1245/s10434-021-10382-7

Cited by 7 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…243 More recently, an IFNα-expressing OAd (5/3 Cox2 ΔE3 ADP IFN) showed significant tumor growth suppression in an esophageal adenocarcinoma (EAC) xenograft model. 244 Similarly, multiple types of OVs can be engineered to overexpress IFNβ to improve anticancer efficacy, including VSV, [245][246][247][248] AdV, 249,250 MeV, 251 VV, 252 Sendai virus (SeV), 253 and NDV. 254 Despite the effective therapeutic effect of OV-encoding IFN, the potential toxicity should attract attention.…”

Section: Interferonsmentioning

confidence: 99%

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Tian

Xie

Yang

2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells unharmed. In addition to direct oncolysis, the essential and attractive aspect of oncolytic virotherapy is based on the intrinsic induction of both innate and adaptive immune responses. To further augment this efficacious response, OVs have been genetically engineered to express immune regulators that enhance or restore antitumor immunity. Recently, combinations of OVs with other immunotherapies, such as immune checkpoint inhibitors (ICIs), chimeric antigen receptors (CARs), antigen-specific T-cell receptors (TCRs) and autologous tumor-infiltrating lymphocytes (TILs), have led to promising progress in cancer treatment. This review summarizes the intrinsic mechanisms of OVs, describes the optimization strategies for using armed OVs to enhance the effects of antitumor immunity and highlights rational combinations of OVs with other immunotherapies in recent preclinical and clinical studies.

show abstract

Section: Interferonsmentioning

confidence: 99%

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Tian

Xie

Yang

2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Recently, IFNα‐expressing OAd (5/3 Cox2δE3 ADP IFN) showed promising antitumor effects in esophageal adenocarcinoma (EAC) xenograft models 107 . In addition to the OVs mentioned above, other OVs, such as VSV, AdV, MeV, VV, Sendai virus, and NDV, showed good antitumor activity after IFNβ expression 106,108–110 …”

Section: Modification Strategies On Ovmentioning

confidence: 99%

Application of oncolytic virus in tumor therapy

Huang

Guo

Lin

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well as activate the innate and adaptive immune systems in patients. Thus, they have been considered as a promising measure for safe and effective cancer treatment. Recently, a few genetically engineered OVs have been developed to further improve the effect of tumor elimination by expressing specific immune regulatory factors and thus enhance the body's antitumor immunity. In addition, the combined therapies of OVs and other immunotherapies have been applied in clinical.Although there are many studies on this hot topic, a comprehensive review is missing on illustrating the mechanisms of tumor clearance by OVs and how to modify engineered OVs to further enhance their antitumor effects. In this study, we provided a review on the mechanisms of immune regulatory factors in OVs. In addition, we reviewed the combined therapies of OVs with other therapies including radiotherapy and CAR-T or TCR-T cell therapy. The review is useful in further generalize the usage of OV in cancer treatment.

show abstract

“…Viruses 2023, 15, 1495 2 of 10 can be utilized to include cytokines, reporter genes, or other therapeutic transgenes in the viral genome [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Viral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification

LaRocca

Jacobsen

Inoko

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafety risks of testing these vectors in animals. We performed adenovirus-based viral shedding studies in murine models to ascertain when it is appropriate to downgrade the animals from Biosafety Level (BSL) 2 to BSL 1 for experimental handling and transport. We utilized intravenous injections of a replication-competent adenovirus and analyzed viral shedding via the collection of buccal and dermal swabs from each animal, in addition to obtaining urine and stool samples. The adenovirus hexon copy number was determined by qPCR, and plaque formation was analyzed to assess the biologic activity of viral particles. Our results demonstrate that after 72 h following viral inoculation, there is no significant quantity of biologically active virus shedding from the animals. This observation suggests that on day 4 following adenovirus injection, mice can be safely downgraded to BSL 1 for the remainder of the experiment with no concern for hazardous exposure to laboratory personnel.

show abstract

Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma

Cited by 7 publications

References 40 publications

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Application of oncolytic virus in tumor therapy

Viral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification

Contact Info

Product

Resources

About